Participated · Series A · May 2025

Hedera Dx develops blood-based liquid biopsy solutions and an AI-native platform that integrates advanced molecular diagnostics with clinical data to inform treatment decisions and support drug development. The company’s offering is designed for hospital in-house testing, aiming to make sophisticated molecular diagnostics locally affordable and easy to adopt. Its platform is already deployed across 11 European countries and the team comprises more than 20 professionals with expertise in genomics, oncology, bioinformatics, AI, and digital health. Hedera positions its real-world data capabilities as a way to generate patient-centric insights that can fuel next-generation oncology treatments. The company was founded in 2021 and is based in Lausanne. The Series A will support continued commercial expansion and further development of its real-world data infrastructure. Hedera Dx develops a blood-based liquid biopsy assay paired with end-to-end software (Hedera Prime) registered as an IVD medical device to enable hospital labs to run clinically actionable cancer tests in-house. The company combines a laboratory assay and streamlined software workflow for analytics, reporting and therapy options to overcome adoption hurdles in hospital laboratories. Hedera Dx plans to launch commercially in the autumn and to implement the first phase of a large oncology Real World Evidence (RWE) clinical testing program. The RWE program aims to create a landmark data asset on real-world usage of liquid biopsy and related cancer patient outcomes. Founded in 2021 by Tommi Lehtonen, Damien Lapray and Christian Meisel, the startup positions its solution to improve access to molecular profiling and therapy selection for cancer patients. The company has just raised new funding to advance these commercialization and clinical-data objectives.

Led · Series A · Nov 2024

Yazen operates an online platform that pairs GLP-1 obesity medications with continuous digital care from a team of doctors, dietitians, psychologists, health coaches and physiotherapists. Active in Sweden, Norway, Denmark, the Netherlands, the United Kingdom, Germany and Spain, the company has treated more than 53,000 patients who have collectively lost over 640 tons. In 2025 Yazen’s revenue jumped 87 % to SEK 330 million, while gross profit doubled to roughly SEK 185 million, underscoring the scalability of its model. The clinic currently manages around 39,000 active patients and employs 290 staff, 220 of whom work clinically, including 130 licensed physicians. Yazen’s evidence-based approach has earned it the title “Weight Loss Treatment of the Year in Europe 2025” from Healthcare Business Review and recognition as the second fastest-growing startup in Europe by Sifted. With a newly secured credit facility, the company plans to accelerate international expansion and broaden access to its comprehensive obesity-care program.